Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Memorial Sloan Kettering
Questions discussed in this category
For patients with rectal cancer being treated along PROSPECT paradigm, would you extrapolate from the IDEA literature and offer 3 months of CAPOX neoadjuvantly, without adjuvant therapy?
1 Answer available
What adjuvant therapy would you give to a patient with resected pT4bN2M0 MSI-H colon cancer and post-op markedly elevated CEA but no metastatic disease seen on imaging?
1 Answer available
How would you approach therapy for a patient with a history of classical HL who achieved a CR to 6 cycles of Brentuximab plus AVD who now presents with widespread non-GC DLBCL?
2 Answers available
How would you treat gray zone lymphoma which initially achieved a CR after 2 cycles of DA-R-EPOCH, but end-of-treatment PET demonstrates progression with new sites of biopsy-proven disease?
1 Answer available
What's the optimal management of stage IA nodal ATLL in a young fit patient?
Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...
1 Answer available
18377
16062
13216
12937
11091
Papers discussed in this category
N Engl J Med,
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
J Clin Oncol, 2020 Dec 23
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Nat Med, 2020 Apr 06
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
J Clin Oncol, 2021 Oct 12
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Nat Cancer, 2020 Aug 03
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
Related Topics
Medical Oncology
NCI-CCC Tumor Board Question
Hematologic Malignancies
Lymphoma
NCI-CCC Lymphoma Tumor Board Question
Gastrointestinal Cancers
Colorectal Cancer
NCI-CCC GI Tumor Board Question
Bone Marrow Transplant
Internal Medicine